Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New prognostic markers in CLL.

Emili Montserrat1

  • 1Department of Hematology, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain. emontse@clinic.ub.es

Hematology. American Society of Hematology. Education Program
|November 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL.

American journal of hematology·2023
Same author

Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature.

British journal of haematology·2023
Same author

Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL.

Journal of hematology & oncology·2022
Same author

mRNA COVID-19 vaccines in patients with chronic lymphocytic leukemia: A systematic review and meta-analysis.

European journal of haematology·2021
Same author

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.

Leukemia·2021
Same author

Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia.

Frontiers in oncology·2021
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Prognosis in chronic lymphocytic leukemia (CLL) is variable. Biological markers like IgVH mutations and CD38 expression offer prognostic insights, aiding treatment decisions and predicting therapy response for better survival outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Chronic lymphocytic leukemia (CLL) prognosis is highly variable.
  • Clinical staging is standard, but biological markers offer independent prognostic value.
  • Standardization and validation of these markers in large trials are needed.

Purpose of the Study:

  • To review current understanding of prognostic markers in CLL.
  • To highlight markers for predicting treatment response and duration.
  • To emphasize the need for further research and standardization.

Main Methods:

  • Review of existing literature on CLL prognostic markers.
  • Analysis of clinical and biological data related to patient outcomes.
  • Discussion of the role of specific genetic and cellular markers.

Related Experiment Videos

Main Results:

  • Serum markers, cytogenetics, IgVH mutations, CD38, and ZAP-70 expression provide prognostic information.
  • del(17p) (P53 abnormalities) and del(11q) (ATM defects) are crucial for prognostication.
  • IgVH mutational status, ZAP-70, and CD38 correlate with treatment response, requiring further study.

Conclusions:

  • Biological markers significantly enhance CLL prognostication beyond clinical staging.
  • Identifying markers for treatment response is a key research area.
  • Eradication of minimal residual disease correlates with improved survival.